Guggenheim raised the firm’s price target on Bristol Myers (BMY) to $72 from $62 and keeps a Buy rating on the shares. The firm has increased its view of the odds of success to 90% for iber/mezi from 33% previously and increased its view of the odds of success to 90% from 75% prior for milvexian in SSP, adding that it continues to recommend investors buy shares ahead of the company’s “series of high-profile, potentially high-reward” Phase 3 catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target raised to $64 from $60 at Citi
- Bristol Myers price target raised to $60 from $55 at Wells Fargo
- Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
- Bristol-Myers Squibb Bets On New Growth Engines
- Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target